Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | DAO | P14920 | 3/20 | 0.51 |
| ▸ | PARP1 | P09874 | 3/20 | 0.49 |
| ▸ | KDM5A | P29375 | 1/20 | 0.47 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4757121 | 0.79 | PARP1 (0.49) | KDM4EALDH1A1DAOPARP1KCNMA1 | |
| SCHEMBL17781102 | 0.78 | PDE2A (0.46) | KDM4EALDH1A1DAOPARP1MAPT | |
| SCHEMBL31298171 | 0.77 | PARP1 (0.49) | KDM4EPARP1 | |
| SCHEMBL18238034 | 0.75 | PARP1 (0.45) | KDM4EALDH1A1DAOPARP1KCNMA1 | |
| SCHEMBL15572559 | 0.74 | KDM4E (0.43) | KDM4EALDH1A1DAOKDM5AADORA2A | |
| SCHEMBL13348756 | 0.74 | KDM4E (0.43) | KDM4EALDH1A1DAOKDM5ARAB9A | |
| SCHEMBL1041260 | 0.73 | KDM4E (0.42) | KDM4EALDH1A1DAOPARP1KDM5A | |
| SCHEMBL260956 | 0.72 | KDM5A (0.43) | KDM4EALDH1A1DAOKDM5AMAPT | |
| SCHEMBL2303102 | 0.71 | PARP1 (0.49) | KDM4EALDH1A1DAOPARP1KCNMA1 | |
| SCHEMBL30575356 | 0.71 | ALDH1A1 (0.53) | KDM4EALDH1A1DAOPARP1KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9163018-B2 | Method of treatment of age-related macular degeneration (AMD) | PRANA BIOTECHNOLOGY INC. (AU) | 2015-10-20 | — | — | US | disclosed |
| US-20140088122-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2014-03-27 | — | — | US | disclosed |
| US-20110071167-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2011-03-24 | — | — | US | disclosed |
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-24 | — | — | US | disclosed |
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-24 | — | — | US | disclosed |
| US-20100144693-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-10 | — | — | US | disclosed |
| US-7692011-B2 | 8-hydroxy and 8-mercapto quinazolinones | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-04-06 | — | — | US | disclosed |
| US-7692011-B2 | 8-hydroxy and 8-mercapto quinazolinones | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-04-06 | — | — | US | disclosed |
| EP-1996553-A2 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | Avanir Pharmaceuticals (US) | 2008-12-03 | — | — | EP | disclosed |
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2007109251-A2 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | TNF, TNFRSF1A, TNFRSF9 | KDM4E 4691/4885ALDH1A1 2365/4885DAO 2289/4885 |
| US-20140088122-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | ALDH1A2, AGER, PDE6C | KDM4E 4624/4885ALDH1A1 238/4885DAO 1648/4885 |
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | ACHE, PSEN1, PSEN2 | KDM4E 3329/4885ALDH1A1 703/4885DAO 1175/4885 |
| US-20100144693-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | ALDH1A2, AGER, PDE6C | KDM4E 4624/4885ALDH1A1 238/4885DAO 1648/4885 |
| US-20110071167-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | ALDH1A2, AGER, PDE6C | KDM4E 4624/4885ALDH1A1 238/4885DAO 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.